Abstract
Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass. PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8). However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.
MeSH terms
-
Aged
-
Antineoplastic Agents / pharmacology
-
CD4 Antigens / biosynthesis*
-
DNA-Binding Proteins / genetics*
-
Dyspnea / diagnosis
-
Gene Rearrangement*
-
HIV Infections / diagnosis
-
Herpesvirus 8, Human / genetics*
-
Herpesvirus 8, Human / metabolism
-
Humans
-
Immunophenotyping
-
Lymphoma, Primary Effusion / complications
-
Lymphoma, Primary Effusion / genetics*
-
Lymphoma, Primary Effusion / therapy
-
Lymphopenia / complications
-
Lymphopenia / therapy*
-
Male
-
Pericardial Effusion
-
Proto-Oncogene Proteins c-bcl-6
-
T-Lymphocytes / metabolism*
Substances
-
Antineoplastic Agents
-
BCL6 protein, human
-
CD4 Antigens
-
DNA-Binding Proteins
-
Proto-Oncogene Proteins c-bcl-6